20088937

Source:http://linkedlifedata.com/resource/pubmed/id/20088937

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0004434, umls-concept:C0348016, umls-concept:C0441655, umls-concept:C0574032, umls-concept:C1433124, umls-concept:C2744251
pubmed:issue	4
pubmed:dateCreated	2010-4-19
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00311090
pubmed:abstractText	Idraparinux is an inhibitor of activated factor X (FXa) with a long half-life allowing once-weekly dosing. Idrabiotaparinux is a biotinylated version of idraparinux; its activity can be reversed with avidin.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101170508
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anticoagulants, http://linkedlifedata.com/resource/pubmed/chemical/Avidin, http://linkedlifedata.com/resource/pubmed/chemical/Biotin, http://linkedlifedata.com/resource/pubmed/chemical/Coagulants, http://linkedlifedata.com/resource/pubmed/chemical/Factor Xa, http://linkedlifedata.com/resource/pubmed/chemical/Oligosaccharides, http://linkedlifedata.com/resource/pubmed/chemical/idrabiotaparinux
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	1538-7836
pubmed:author	pubmed-author:BoëlleEE, pubmed-author:CortezPP, pubmed-author:DestorsJ-MJM, pubmed-author:PatzHH, pubmed-author:SanderinkGG, pubmed-author:TrelluMM
pubmed:issnType	Electronic
pubmed:volume	8
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	722-9
pubmed:meshHeading	pubmed-meshheading:20088937-Adolescent, pubmed-meshheading:20088937-Adult, pubmed-meshheading:20088937-Anticoagulants, pubmed-meshheading:20088937-Avidin, pubmed-meshheading:20088937-Biotin, pubmed-meshheading:20088937-Coagulants, pubmed-meshheading:20088937-Dose-Response Relationship, Drug, pubmed-meshheading:20088937-Double-Blind Method, pubmed-meshheading:20088937-Factor Xa, pubmed-meshheading:20088937-Female, pubmed-meshheading:20088937-Humans, pubmed-meshheading:20088937-Infusions, Intravenous, pubmed-meshheading:20088937-Injections, Subcutaneous, pubmed-meshheading:20088937-Lower Extremity, pubmed-meshheading:20088937-Male, pubmed-meshheading:20088937-Oligosaccharides, pubmed-meshheading:20088937-Prospective Studies, pubmed-meshheading:20088937-Recurrence, pubmed-meshheading:20088937-Time Factors, pubmed-meshheading:20088937-Treatment Outcome, pubmed-meshheading:20088937-Venous Thrombosis, pubmed-meshheading:20088937-Young Adult
pubmed:year	2010
pubmed:articleTitle	Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion.
pubmed:affiliation	Sanofi-aventis Recherche & Développement, Clinical and Pharmacology Department, Chilly-Mazarin, France. isabelle.paty@sanofi-aventis.com
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Clinical Trial, Phase I, Clinical Trial, Phase III